INT23350

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 1985
Last Reported 2005
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 10
Disease Relevance 3.48
Pain Relevance 0.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (CFI) extracellular space (CFI) extracellular region (CFI)
Anatomy Link Frequency
plasma 1
CFI (Homo sapiens)
Pain Link Frequency Relevance Heat
abdominal pain 8 99.12 Very High Very High Very High
carbamazepine 6 63.84 Quite High
Versed 14 62.44 Quite High
rapifen 8 50.16 Quite High
lidocaine 4 23.72 Low Low
cytokine 4 5.00 Very Low Very Low Very Low
Paracetamol 4 5.00 Very Low Very Low Very Low
Potency 4 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 24 99.68 Very High Very High Very High
Abdominal Pain 8 99.12 Very High Very High Very High
Hereditary Angioedema 6 98.96 Very High Very High Very High
Reprotox - General 1 10 96.08 Very High Very High Very High
Threatened Abortion 2 92.12 High High
Toxicity 32 87.80 High High
Arrhythmia Under Development 6 5.00 Very Low Very Low Very Low
Hypertension 4 5.00 Very Low Very Low Very Low
Rhabdomyolysis 4 5.00 Very Low Very Low Very Low
Cv General 2 Under Development 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is believed that the in vivo inhibitory effect of a mechanistic inactivator is more prominent after multiple dosing and lasts longer than that of a reversible inhibitor (Lin and Lu 1998).
Negative_regulation (effect) of inactivator
1) Confidence 0.05 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.09 Pain Relevance 0
The in vivo inhibitory effect of a mechanistic inactivator is more prominent after multiple dosing and lasts longer than that of a reversible inhibitor (Lin and Lu 1998).
Negative_regulation (effect) of inactivator
2) Confidence 0.05 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0 Pain Relevance 0.11
Laboratory examination revealed hypocomplementemia, marked depletion of the fourth component of complement and low level of C1-inactivator.
Negative_regulation (depletion) of C1-inactivator
3) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Abstract Doc Link 3610041 Disease Relevance 0.42 Pain Relevance 0.10
And the condition that complete functional deficiency of C1-inactivator was main role in this circuit.
Negative_regulation (deficiency) of C1-inactivator
4) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Abstract Doc Link 3610041 Disease Relevance 0.36 Pain Relevance 0.06
[A case report of hereditary angioedema and studies on the serum components of complement, C1-inactivator and proteinase inhibitors during edema attack].
Negative_regulation (inhibitors) of C1-inactivator associated with pressure and volume under development and hereditary angioedema
5) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Title Doc Link 3610041 Disease Relevance 0.47 Pain Relevance 0.10
Laboratory examination revealed hypocomplementemia, marked depletion of the fourth component of complement and low level of C1-inactivator.
Negative_regulation (level) of C1-inactivator
6) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Abstract Doc Link 3610041 Disease Relevance 0.42 Pain Relevance 0.10
The fourth component of complement and C1-inactivator were markedly depleted in remission and attack.
Negative_regulation (depleted) of C1-inactivator
7) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Abstract Doc Link 3610041 Disease Relevance 0.41 Pain Relevance 0.08
Remarkable depletion was found in antithrombin III and esterase inhibition activity of C1-inactivator during attack.
Negative_regulation (inhibition) of C1-inactivator
8) Confidence 0.04 Published 1987 Journal Hokkaido Igaku Zasshi Section Abstract Doc Link 3610041 Disease Relevance 0.39 Pain Relevance 0.08
Also, a significant reduction in plasminogen and elevated C1-inactivator was observed in patients with poor prognosis.
Negative_regulation (reduction) of C1-inactivator
9) Confidence 0.00 Published 1985 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 2411832 Disease Relevance 0.40 Pain Relevance 0.10
In these patients the following substances in plasma were determined: Prekallikrein, alpha 2-plasmin inhibitor, alpha 1-antitrypsin, alpha 2-macroglobulin, C1-inactivator, antithrombin-III, plasminogen, fibrinogen, fibrin degradation products (FDP).
Negative_regulation (inhibitor) of C1-inactivator in plasma
10) Confidence 0.00 Published 1985 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 2411832 Disease Relevance 0.51 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox